Isomer-specific effects of conjugated @entity4722 on lipid peroxidation in @entity1 : regulation by XXXX and cyclo-oxygenase-2 inhibitor.

@entity1 @entity18314 @entity13586 @entity7707 @entity1881 @entity2247 @entity4722
We have found previously that supplementation with conjugated @entity4722 (CLA) induces lipid peroxidation and inflammation in @entity1 as indicated by an increase of @entity7707 (PGF2alpha) and @entity18314 respectively. The present study was undertaken firstly to study the regulatory mechanisms behind these effects, and secondly to see if these effects are specific to different isomers of CLA. Sixty healthy @entity1 and @entity1 , divided into six groups, were given a @entity2247 inhibitor ( @entity13586 ; 12 mg/day), @entity1881 (200 mg/day) or neither treatment (control group) over a period of 6 weeks. During the last 4 weeks, three groups were given a CLA preparation (3.5 g/day) mainly containing the isomers cis-9, trans-11 and trans-10, cis-12 (CLA mix), and the three other groups a CLA preparation mainly containing the isomer trans-10, cis-12 (CLA 1012; 4.0 g/day). Treatment with @entity1881 or @entity2247 inhibitor did not alter the basal urinary levels of either @entity7707 or @entity18314 . Both CLA preparations induced an increase in @entity7707 and @entity18314 in the urine, with a larger increase being found in the CLA 1012 group. Treatment with the @entity2247 inhibitor suppressed the increase in urinary @entity18314 in the CLA 1012 group, but not in the CLA mix group. Neither the @entity2247 inhibitor nor @entity1881 had any effect on @entity7707 levels after supplementation with CLA. The CLA-induced production of PGF2alpha metabolites is probably partially mediated by @entity2247 . Levels of the induced lipid peroxidation may be dependent on the isomeric property of CLA.
